-
Recent Posts
Categories
- Anesthesiology
- Avandia
- Biomedical Engineering
- Cardiology
- Clinical Trials
- Clinics
- Consumer Products
- Counterfeit Products
- Critical Care Medicine
- Dentistry
- Dermatology
- Emergency Rooms
- Endocrinology
- Eye Care
- Family Practice
- FDA 2011
- FDA 2012
- FDA 2013
- FDA Label Change
- FDA Notice
- FDA Recall
- FDA Safety Communication
- FDA Warning
- Gastroenterology
- Healthcare Professionals
- Hematology
- Home Care
- Hospitals
- Infectious Disease
- Internal Medicine
- Laboratory
- multiple sclerosis (MS)
- Nephrology
- Neurology
- Nursing
- OBGYN
- Oncology
- Ophthalmology
- Orthopaedic Surgery
- Pain Management
- Patients
- Pediatrics
- Pharmacy
- Physical Medicine
- Psychiatry
- Pulmonology
- Radiology
- Rheumatology
- Risk Manager
- Surgery
- Uncategorized
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
Category Archives: Hematology
Omontys peginesatide Injection by Affymax and Takeda Recall
Omontys (peginesatide) Injection by Affymax and Takeda: Recall of All Lots – Serious Hypersensitivity Reactions AUDIENCE: Patients, Healthcare Professionals, Hematology ISSUE: Affymax, Inc. and Takeda Pharmaceutical Company Limited along with the U.S. Food and Drug Administration (FDA) are informing the … Continue reading
Posted in FDA 2013, FDA Recall, Healthcare Professionals, Hematology, Patients
Tagged Affymax, drug risks, FDA recall, Healthcare Professionals, Hematology, Injection, Omontys, Omontys peginesatide Injection by Affymax and Takeda Recall, Patients, peginesatide, Recall, Takeda
Comments Off
Argatroban Injection 50 mg 50 mL 1 mg mL Recall
Argatroban Injection 50 mg/50 mL (1 mg/mL): Recall – Potential for Visible Particulates AUDIENCE: Pharmacy, Hematology ISSUE: Eagle Pharmaceuticals Inc., supplier to The Medicines Company, issued a voluntary recall of all four (4) lots of Argatroban Injection, 50 mg per 50 mL … Continue reading
Posted in FDA 2012, FDA Recall, Hematology, Pharmacy
Tagged 1 mg mL, 50 mg 50 mL, Argatroban Injection, Argatroban Injection 50 mg 50 mL 1 mg mL Recall, drug risks, Eagle Pharmaceuticals Inc., FDA recall, Recall, The Medicines Company
Comments Off
Adcetris (brentuximab vedotin) Drug Safety Communication
Adcetris (brentuximab vedotin): Drug Safety Communication – Progressive Multifocal Leukoencephalopathy and Pulmonary Toxicity AUDIENCE: Oncology, Hematology, Neurology ISSUE: FDA notified healthcare professionals that two additional cases of progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection that can result in … Continue reading
Posted in FDA 2011, FDA Label Change, FDA Notice, FDA Warning, Hematology, Neurology, Oncology
Tagged Adcetris, Adcetris (brentuximab vedotin) Drug Safety Communication, brentuximab vedotin, drug risks, Drug Safety Communication, FDA notice, FDA warning, Progressive Multifocal Leukoencephalopathy, Pulmonary Toxicity, safety label changes
Comments Off
Pradaxa (dabigatran etexilate mesylate) Drug Safety Communication
Pradaxa (dabigatran etexilate mesylate): Drug Safety Communication – Safety Review of Post-Market Reports of Serious Bleeding Events AUDIENCE: Cardiology, Pharmacy, Hematology ISSUE: FDA is evaluating post-marketing reports of serious bleeding events in patients taking Pradaxa (dabigatran etexilate mesylate). Bleeding that … Continue reading
Posted in Cardiology, FDA 2011, FDA Notice, FDA Warning, Hematology, Pharmacy
Tagged Cardiology, dabigatran etexilate mesylate, drug risks, Drug Safety Communication, FDA notice, FDA warning, Hematology, Pharmacy, Pradaxa, Pradaxa (dabigatran etexilate mesylate) Drug Safety Communication
Comments Off
Sprycel (dasatinib) Drug Safety Communication
Sprycel (dasatinib): Drug Safety Communication – Risk of Pulmonary Arterial Hypertension AUDIENCE: Hematology, Oncology ISSUE: FDA notified healthcare professionals that Sprycel (dasatinib) may increase the risk of a rare but serious condition in which there is abnormally high blood pressure … Continue reading
Posted in FDA 2011, FDA Notice, Hematology, Oncology
Tagged dasatinib, FDA notice, Hematology, Oncology, Risk of Pulmonary Arterial Hypertension, Sprycel, Sprycel (dasatinib)
Comments Off